Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT05013216

Title field or adapter rule

{'original_value': 'Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:24.034179+00:00

Published At

2026-10-06T00:00:00+00:00

Record Updated At

2026-10-06

Source Retrieved At

2026-10-31T22:17:54.613222+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["High Risk Cancer", "Pancreatic Cancer"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-06", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT05013216"

protocolSection.identificationModule.officialTitle

"Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer"

protocolSection.statusModule.overallStatus

"ACTIVE_NOT_RECRUITING"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• High Risk Cancer (protocolSection.conditionsModule.conditions)
• Pancreatic Cancer (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Cohort A: Patients at high risk of developing pancreatic cancer.'], 'description': '1. KRAS peptide vaccine with poly-ICLC adjuvant will be administered on Prime week 1, 3, and 5. Boost vaccinations with will be administered at week 13. All subjects will return to the study site approximately 28 days (+ 7 days) after the last vaccination for an End of Treatment (EOT) and safety evaluation.\n2. Drug: up to 1.8 mg KRAS peptide vaccine + 0.5mg Poly-ICLC', 'name': 'Cohort A: Patients at high risk of developing pancreatic cancer.', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Cohort B: Patients must have evidence of a pancreatic cystic neoplasm'], 'description': 'Patients will receive KRAS peptide vaccine with poly-ICLC adjuvant as two prime vaccinations on weeks 1 and 2. Surgery is considered standard of care. Surgery will occur at the discretion of the treating hepatobiliary surgeon and is not dictated by this protocol. Subjects will return to the study site approximately at week 4 (+ 7 days) for a safety evaluation prior to surgery. Subjects will have an End of Treatment (EOT) visit at study Week 8 (+ 7 days).', 'name': 'Cohort B: Patients must have evidence of a pancreatic cystic neoplasm', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Cohort A: Patients at high risk of developing pancreatic cancer. (protocolSection.armsInterventionsModule.interventions[].name)
• Cohort B: Patients must have evidence of a pancreatic cystic neoplasm (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.